immune mediated News
-
T3 Pharma wins prestigious Falling Walls Venture Award for its bacterial cancer therapy
T3 Pharmaceuticals (“T3 Pharma”), a biotech company with a focus on immuno-oncology, today announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models. The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists ...
-
Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial launch. This latest contract action, ...
-
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
-
New Study Establishes Cytovale IntelliSep Test in the Rapid Diagnosis of Sepsis
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal PLOS ONE evaluating its IntelliSep test in the rapid diagnosis of sepsis in the hospital emergency department. Data from the study, “Development and validation of a cellular ...
-
Cipla enters partnership to provide affordable oncology biosimilars to South Africa
Cipla Medpro and the wholly owned subsidiary of Cipla Limited, India have finalised a partnership agreement with the global biotechnology company mAbxience, to get oncology and respiratory-related biosimilars to South Africa. These medicine products for the treatment of cancer are on the WHO Model List of Essential Medicines. The mAbxience partnership will enable Cipla to continue its ethos of ...
By mAbxience
-
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
Low dose arm of the study met the co-primary endpoints of percent change in Eczema Area and Severity Index (EASI) score from baseline, and incidence of treatment-emergent adverse events, through week 16 First trial to assess the effects of blocking OX40-Ligand, a key immune system regulator, in patients with moderate-to-severe atopic dermatitis Data support amlitelimab as a potential ...
-
Asthma Rates Increasing across the Mid-Atlantic Region
Recently, the U.S. Centers for Disease Control (CDC) announced that an additional 4.3 million people were diagnosed with asthma between 2001 and 2009. These new figures bring the total number of asthma suffers in the United States to approximately 1 in 12 or 25 million people. "Despite the fact that outdoor air quality has improved, we've reduced two common asthma triggers - secondhand smoke ...
-
Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease. The trial, AKST4290-211 (TEAL), is funded in part by The Michael J. Fox Foundation for ...
-
Cytovale IntelliSep Test Demonstrates Potential to Rapidly Risk-Stratify Suspected COVID-19 Patients in New Study
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, today announced a new study on its investigational IntelliSep test has been published in the peer-reviewed journal PLOS ONE. The study, “Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the ...
-
New Study Supports Cytovale IntelliSep Test as Promising Tool to Aid in the Rapid Diagnosis of Sepsis in the Emergency Department
Cytovale, a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal Critical Care Explorations (CCE) evaluating its IntelliSep test as a tool in the rapid diagnosis of sepsis in the hospital emergency department (ED). Data from the study, ...
-
Cytovale Begins Enrollment in FDA 510(k) Clinical Validation Study of IntelliSep Rapid Sepsis Test
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED). The trial, A Clinical Validation Solving the Question of ...
-
Evolve BioSystems, Inc. Announces the Use of Activated B. infantis EVC001 by International Consortium to Study the Prevention of Type 1 Diabetes in Children
Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children. The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries. The Leona M. and Harry B. ...
-
AstraZeneca to Acquire Alexion, Accelerating the Company`s Strategic and Financial Development
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on ...
-
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburn EsoCap is currently conducting a randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients in four European countries with its lead candidate ESO-101 To help raise awareness of the medical condition, EsoCap supports EUREOS and ...
By EsoCap AG
-
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
SAN DIEGO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, ...
-
NIH statement on Asthma Awareness Month
For Asthma Awareness Month 2013, the National Institutes of Health stands with the international community to renew our dedication to improving the quality of life for the estimated 300 million people living with asthma worldwide. To most effectively manage asthma, we need to address the disproportionate impact of the disease on minorities and families at or below the poverty line. NIH is ...
-
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some ...
-
CD ComputaBio Announces PD-L1 Targeting Service for Anticancer Drug Research
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of PD-L1 targeting service for cancer research. Over the past decade, ...
-
Asthma Awareness Month 2014: NIH Continues its Commitment to Asthma Research
May is Asthma Awareness Month, and the National Institutes of Health emphasizes the scientific progress being made in asthma research, from basic science, such as how lung cells work, to clinical trials on current and future treatments for the disease. NIH-led research includes studies of environmental factors, how the body’s own defense system plays a role, and the microbiome — all ...
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you